These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2962910)

  • 1. Continuous, high-dose progestogen treatment of endometrial cancer.
    Szarvas Z; Zsolnai B; Gimes G; Hidvégi J
    Gynecol Obstet Invest; 1987; 24(4):262-6. PubMed ID: 2962910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of long-term high-dose progesterone (Depo-Provera) therapy on endometrial carcinoma].
    Szarvas Z; Zsolnai B; Gimes G; Hidvégi J
    Morphol Igazsagugyi Orv Sz; 1985 Oct; 25(4):253-60. PubMed ID: 2933583
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of progestogen (Depo-Provera) on annulate lamellae in endometrial carcinoma.
    Szarvas Z; Zsolnai B
    Acta Chir Hung; 1984; 25(4):269-76. PubMed ID: 6240879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
    Thurzó L
    Zentralbl Gynakol; 1990; 112(17):1111-5. PubMed ID: 2148245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Surface changes in endometrial cancer under the effect of large doses of progestogen (Depo-Provera)].
    Szarvas Z; Zsolnai B
    Morphol Igazsagugyi Orv Sz; 1984 Apr; 24(2):92-9. PubMed ID: 6717452
    [No Abstract]   [Full Text] [Related]  

  • 6. [Estrogen and progesterone receptors in endometrial carcinoma during high-dose progestogen (Depo-Provera) therapy].
    Thurzó L; Sas M; Falkay G
    Orv Hetil; 1986 Oct; 127(43):2613-6. PubMed ID: 2947029
    [No Abstract]   [Full Text] [Related]  

  • 7. Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients.
    Lindahl B; Willén R
    Anticancer Res; 1991; 11(1):403-6. PubMed ID: 1826823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Provera the ideal progestogen for addition to postmenopausal estrogen therapy?
    Lane G; Siddle NC; Ryder TA; Pryse-Davies J; King RJ; Whitehead MI
    Fertil Steril; 1986 Mar; 45(3):345-52. PubMed ID: 3005052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of progestogen therapy with the conventional treatment of endometrial carcinoma.
    Luukkainen T; Karjalainen O
    Bull Schweiz Akad Med Wiss; 1970 Oct; 25(4-6):581-5. PubMed ID: 5510182
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytochemical examinations of Ca, cytochrome oxidase and succinate dehydrogenase enzymes in endometrium carcinomatous tissue after high dose progestogen treatment.
    Szarvas Z; Balogh I; Patai K
    Acta Morphol Hung; 1988; 36(3-4):177-83. PubMed ID: 2855777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progesterone receptors in endometrial carcinoma and their response to medroxyprogesterone acetate].
    Feng YJ; Zhang XY
    Zhonghua Fu Chan Ke Za Zhi; 1989 May; 24(3):153-5, 189. PubMed ID: 2530067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cell surface changes after high-dosage progesterone treatment in endometrial carcinoma].
    Szarvas Z; Zsolnai B
    Zentralbl Gynakol; 1984; 106(14):1010-7. PubMed ID: 6239468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistological localization of pregnancy-associated endometrial alpha 2-globulin (alpha 2-PEG) in endometrial adenocarcinoma and effect of medroxyprogesterone acetate.
    Wood PL; Waites GT; MacVicar J; Davidson AC; Walker RA; Bell SC
    Br J Obstet Gynaecol; 1988 Dec; 95(12):1292-8. PubMed ID: 2975952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of progestogens in the primary treatment of endometrial carcinoma.
    Macdonald RR; Thorogood J; Mason MK
    Br J Obstet Gynaecol; 1988 Feb; 95(2):166-74. PubMed ID: 2964861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer.
    Lewis GC; Slack NH; Mortel R; Bross ID
    Gynecol Oncol; 1974 Aug; 2(2-3):368-76. PubMed ID: 4616883
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of advanced endometrial cancer].
    Okada H; Yamamoto T
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1848-55. PubMed ID: 2144105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant gestagen therapy in stage I endometrial cancer].
    Lahousen M; Pickel H
    Zentralbl Gynakol; 1988; 110(16):1013-7. PubMed ID: 2973195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma.
    Piver MS; Barlow JJ; Lurain JR; Blumenson LE
    Cancer; 1980 Jan; 45(2):268-72. PubMed ID: 6985833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy with gestagens in hyperplastic changes of the endometrium].
    Griesinger R; Schindler AE
    Geburtshilfe Frauenheilkd; 1986 Oct; 46(10):690-2. PubMed ID: 2948865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experiences with Depo-Provera (medroxyprogesterone) in the treatment of kidney tumors].
    Balogh F; Romics I
    Z Urol Nephrol; 1987 Aug; 80(8):449-53. PubMed ID: 2961162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.